Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 5:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 17,848 matching trials from the live ClinicalTrials.gov search.
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Pioglitazone placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years to 83 Years
Enrollment
3,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
34
States / cities
Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more
Conditions
Multiple Sclerosis (MS)
Interventions
elezanumab, placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 35 more
Conditions
Non Infectious Uveitis
Interventions
DE-109 Intravitreal Injections, Sham Procedure, DE-109 Intravitreal Injections (Open Label)
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement

NCT06489431
Conditions
Erectile Dysfunction, Penile Prosthesis; Complications, Infection or Inflammation
Interventions
Chlorhexidine, Gentamicin, Rifampin
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Mountain View, California • Chicago, Illinois • Des Plaines, Illinois
Conditions
Blood Coagulation Disorders
Interventions
Warfarin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With 11q Aberration, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Gray-Zone Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Nivolumab, Varlilumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more
Conditions
Fragile X Syndrome
Interventions
Placebo, RO4917523
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 13 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Long Beach, California • Sacramento, California • San Diego, California + 17 more
Conditions
Breast Cancer
Interventions
tamoxifen citrate, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
26 Years to 120 Years · Female only
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
305
States / cities
Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 235 more
Conditions
Adenomatous Polyposis Coli
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
23
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Omaha, Nebraska + 16 more
Conditions
Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions
Bevacizumab, Irinotecan Hydrochloride, Temozolomide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
93
States / cities
Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 73 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib, Atezolizumab, Erlotinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
10
States / cities
Orange, California • New Haven, Connecticut • Orlando, Florida + 5 more
Conditions
Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Assessment of Therapy Complications, Carboplatin, Filgrastim, Paclitaxel, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
75 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
357
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 245 more
Conditions
Skin Squamous Cell Carcinoma, Metastatic Skin Cancer
Interventions
Avelumab, Cetuximab
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
428
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 274 more
Conditions
Osteogenesis Imperfecta
Interventions
Bisphosphonate, Setrusumab
Drug · Biological
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
2 Years to 6 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more
Conditions
Breast Cancer
Interventions
Amcenestrant-matching placebo, SAR439859, Palbociclib, Letrozole, Goserelin, Letrozole-matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
45
States / cities
Daphne, Alabama • Glendale, Arizona • Tucson, Arizona + 40 more
Conditions
Granulomatous Colitis, Crohn's Disease, Crohn's Enteritis, Granulomatous Enteritis
Interventions
BMS-986165, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
52
States / cities
Los Angeles, California • Aurora, Colorado • Hamden, Connecticut + 42 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

TMW Community-Wide Demonstration Project

NCT04330131
Conditions
Language Development
Interventions
3Ts - Newborn, 3Ts - Well Baby, 3Ts - Let's Talk!
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
16 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
West Palm Beach, Florida • Chicago, Illinois
Conditions
HIV Seropositivity
Interventions
Social Network Support Intervention
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 49 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chicago, Illinois + 1 more
Conditions
Sickle Cell Disease
Interventions
Epeleuton
Drug
Lead sponsor
Afimmune
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Farmington, Connecticut • Washington D.C., District of Columbia + 11 more
Conditions
Recurrent Glioblastoma
Interventions
Cediranib, Lomustine Chemotherapy, Placebo Cediranib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Pheonix, Arizona • Los Angeles, California + 18 more
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
26
States / cities
Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 21 more
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
continuous glucose monitor based insulin bolus calculator
Device
Lead sponsor
Welldoc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Fibrosarcoma NOS, Myxofibrosarcoma, Angiosarcoma, Osteosarcoma, Extraskeletal, Dedifferentiated Liposarcoma, Myxoid Liposarcoma, Pleomorphic Liposarcoma, Myxoid Pleomorphic Liposarcoma, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, Malignant Tenosynovial Giant Cell Tumor of Soft Tissue, Epithelioid Hemangioendothelioma, Glomus Tumor, Inflammatory Leiomyosarcoma, Leiomyosarcoma, Ossifying Fibromyxoid Tumor, Malignant, Myoepithelioma, Synovial Sarcoma, Epithelioid Sarcoma, Perineurioma, Malignant, Clear Cell Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Granular Cell Tumor, Malignant, Melanotic Malignant Nerve Sheath Tumor, Malignant Peripheral Nerve Sheath Tumor, Perivascular Epithelioid Tumor, Malignant, Intimal Sarcoma, Myoepithelial Carcinoma, Undifferentiated Sarcoma, Pleomorphic Sarcoma, Undifferentiated, Round Cell Sarcoma, Undifferentiated, NTRK-Rearranged Spindle Cell Neoplasm, Phosphaturic Mesenchymal Tumor, Malignant, Round Cell Sarcoma, Well Differentiated Liposarcoma, Giant Cell Tumor of Soft Parts NOS, Low Grade Myofibroblastic Sarcoma, Dermatofibrosarcoma Protuberans, Fibrosarcomatous
Interventions
Surgical resection, Proton beam radiation therapy, Pazopanib, Ifosfamide, Doxorubicin, Selinexor
Procedure · Radiation · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Baton Rouge, Louisiana + 4 more
Conditions
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
Interventions
ANV419
Drug
Lead sponsor
Anaveon AG
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 6 more